Table 8.
Patients’ characteristics presented after the group was broken down by TSQ-36 scores while on therapy with LT4 (L, M, or H)
| Parameters | L (N = 30) | M (N = 25) | H (N = 20) | P value |
|---|---|---|---|---|
| Age | 49.8 (11.1) | 49.7 (8.29) | 51.0 (7.64) | 0.877 |
| Sex | ||||
| Female | 24 (80.0%) | 18 (72.0%) | 16 (80.0%) | 0.779 |
| Male | 6 (20.0%) | 7 (28.0%) | 4 (20.0%) | |
| Genotype_group.y | ||||
| Heterozygous | 14 (46.7%) | 15 (60.0%) | 12 (60.0%) | 0.679 |
| Ala92-DIO2 | 3 (10.0%) | 3 (12.0%) | 3 (15.0%) | |
| Thr92-DIO2 | 13 (43.3%) | 7 (28.0%) | 5 (25.0%) | |
| Etiology | ||||
| Autoimmune | 19 (63.3%) | 16 (64.0%) | 11 (55.0%) | 0.795 |
| Nonautoimmune | 11 (36.7%) | 9 (36.0%) | 9 (45.0%) | |
| Preference | ||||
| LT4 | 12 (40.0%) | 1 (4.0%) | 2 (10.0%) | 0.00892 |
| DTE | 9 (30.0%) | 13 (52.0%) | 7 (35.0%) | |
| LT4 + LT3 | 5 (16.7%) | 8 (32.0%) | 10 (50.0%) | |
| No preference | 4 (13.3%) | 3 (12.0%) | 1 (5.0%) | |
| Preference for LT4 | ||||
| Yes | 12 (40.0%) | 1 (4.0%) | 2 (10.0%) | 0.0017 |
| No | 18 (60.0%) | 24 (96.0%) | 18 (90.0%) | |
| TSH (0.27-4.68 mU/μL) | 1.93 (1.31) | 1.54 (1.23) | 1.32 (1.24) | 0.23 |
| T4 (4.5-12 mcg/dL) | 8.20 (2.36) | 8.77 (1.34) | 8.45 (2.60) | 0.63 |
| T3 (60-181 ng/dL) | 102 (26.9) | 103 (14.5) | 105 (23.0) | 0.896 |
| Reverse T3 (11-32 ng) | 19.6 (5.62) | 20.3 (4.71) | 22.6 (6.35) | 0.171 |
TSQ-36 questionnaire scores presented as low (L), medium (M), and high (H); TSQ-36: L = 1-13, M = >13-21, H = >21-33; for age, serum TSH, T4, T3, and reverse T3 values are mean (SD). For categorical variables, P value reports the results of a Fisher exact test; for continuous variables, P value reports the results of a linear model evaluating the effect of TSQ score quantile.
Abbreviation: TSQ-36, 36-point thyroid symptom questionnaire.